When CD155 is up-regulated in tumor cells, co-stimulatory molecule DNAM-1 recognizes and binds to tumor cells to stimulate immunity, while the inhibitory receptor TIGIT induces intracellular signaling to exert inhibitory effects. Here, CD226 is linked to neoplasm.